Etanercept

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lupus Erythematosus, Discoid

Conditions

Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous

Trial Timeline

Feb 1, 2016 → Dec 31, 2017

NCT ID

NCT02656082

About Etanercept

Etanercept is a phase 2 stage product being developed by Pfizer for Lupus Erythematosus, Discoid. The current trial status is completed. This product is registered under clinical trial identifier NCT02656082. Target conditions include Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Erythematosus, Discoid were approved

Approved (8) Terminated (7) Active (7)

✅tacrolimusAstellas PharmaApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00063869	Phase 2	Completed	—	Mar 1, 2005	Pulmonary Fibrosis
NCT04507776	Pre-clinical	Completed	Sep 1, 2020	Oct 1, 2020	Spondyloarthrosis
NCT04507763	Pre-clinical	Completed	Aug 1, 2020	Oct 1, 2020	Ankylosing Spondylitis
NCT04267614	Pre-clinical	Completed	Nov 1, 2018	Dec 1, 2018	Arthritis Rheumatoid
NCT02656082	Phase 2	Completed	Feb 1, 2016	Dec 31, 2017	Lupus Erythematosus, Discoid
NCT02509026	Approved	Completed	Sep 24, 2015	Sep 6, 2019	Spondylitis, Ankylosing
NCT02378506	Phase 3	Completed	Apr 1, 2015	Jun 1, 2016	Arthritis, Rheumatoid
NCT02486302	Pre-clinical	Completed	Mar 24, 2015	Dec 11, 2017	Rheumatoid Arthritis
NCT02322580	Pre-clinical	Completed	Jan 1, 2015	Nov 1, 2016	Psoriasis
NCT01421069	Phase 3	Completed	Oct 10, 2011	Feb 4, 2021	Juvenile Idiopahtic Arthritis
NCT01068353	Phase 2	Completed	Jan 1, 2011	—	Alzheimer's Disease
NCT01793285	Pre-clinical	Completed	Dec 1, 2010	Feb 1, 2012	Ankylosing Spondylitis
NCT01100034	Pre-clinical	Completed	Nov 19, 2010	Sep 24, 2018	Psoriasis
NCT00913458	Approved	Completed	Sep 1, 2009	Dec 1, 2012	Active Rheumatoid Arthritis
NCT00962741	Phase 3	Completed	Sep 1, 2009	Jan 1, 2013	Arthritis, Juvenile Idiopathic
NCT00910273	Approved	Terminated	Jul 1, 2009	Oct 1, 2011	Ankylosing Spondylitis
NCT00768053	Approved	Completed	Oct 1, 2008	Apr 1, 2010	Rheumatoid Arthritis
NCT00705042	Phase 1	Completed	Jul 1, 2008	Nov 1, 2008	Healthy Subjects
NCT00544557	Pre-clinical	Completed	Oct 1, 2007	May 1, 2014	Ankylosing Spondylitis
NCT00581555	Approved	Completed	Oct 1, 2007	Nov 1, 2009	Psoriasis

Competing Products

20 competing products in Lupus Erythematosus, Discoid

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus	Astellas Pharma	Pre-clinical	26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisone	Astellas Pharma	Phase 3	32
tacrolimus	Astellas Pharma	Approved	35
Tacrolimus capsules + Cyclophosphamide injections + Prednisone	Astellas Pharma	Phase 3	40
E6742	Eisai	Phase 1/2	32
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks	Eli Lilly	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY3471851 + Placebo	Eli Lilly	Phase 1	29
LY3471851 + Placebo	Eli Lilly	Phase 2	35